A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders

Pediatric Blood and Cancer

Volumn 51, Issue 6, 2008, Pages 774-777

  Sato, Tomonobu ^a   Kobayashi, Ryoji ^a   Yasuda, Kazue ^a   Kaneda, Makoto ^b   Iguchi, Akihiro ^c   Kobayashi, Kunihiko ^a  

^a SAPPORO HOKUYU HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Cefozopran; Ceftazidime; Children; Febrile neutropenia; Piperacillin tazobactam; Randomized controlled trial

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GLUCAN; CEFOZOPRAN; CEFTAZIDIME; FUNGUS ANTIGEN; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOSIS; NEWBORN; OPEN STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS ORALIS; STREPTOCOCCUS SANGUINIS; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 56749177384     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21692     Document Type: Article

References (20)

1. Petrilli AS, Bianchi A, Kusano E, et al. Fever and granulocytopenia in children with cancer: A study of 299 episodes with two-treatment protocol in Brazil. Med Pediatr Oncol 1993;21:356-361.
2. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. Br J Haematol 1997;99:580-588.
3. EORTC International Antimicrobial Therapy Cooperative Group. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-452.
4. Freifeld A, Walsh T, Marshall D. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-176.
5. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: A realistic goal? Scand J Infect Dis 1995;96:34-37.
6. Kutluk T, Kurne O, Akyüz C, et al. Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer 2004;42:284-286.
7. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558.
8. Rhomberg PR, Fritsche TR, Sader HS, et al. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis 2006;56:57-62.
9. Thom KA, Johnson JA, Strauss SM, et al. Increasing prevalence of gastrointestinal colonization with ceftazidime-resistant gram-negative bacteria among intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:1240-1246.
10. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 2007;57:423-428.
11. Huang SS, Lee MH, Leu HS. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. J Microbiol Immunol Infect 2006;39:496-502.
12. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
13. Cherif H, Björkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for hematological malignancies. Scand J Infect Dis 2004;36:593-600.
14. Roberts JA, Webb SA, Lipman J. Cefepime versus ceftazidime: Considerations for empirical use in critically ill patients. Int J Antimicrob Agents 2007;29:117-128.
15. Lindblad R, Rodjer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia - A randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998;30:237-243.
16. Wang FD, Liu CY, Hsu HC, et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999;45:370-379.
17. Viscoli C, Cometta A, Kern WV, et al. International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer: Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006;12:212-216.
18. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: Systemic review and metaanalysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176-189.
19. Glasmacher A, von Lilienfeld-Toal M, Schulte S, et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11:17-23.
20. Kebudi R, Görgün O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001;36:434-441.